1. Home
  2. GRDN vs HRMY Comparison

GRDN vs HRMY Comparison

Compare GRDN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardian Pharmacy Services Inc.

GRDN

Guardian Pharmacy Services Inc.

HOLD

Current Price

$37.41

Market Cap

2.4B

ML Signal

HOLD

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$39.20

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRDN
HRMY
Founded
2004
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.2B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
GRDN
HRMY
Price
$37.41
$39.20
Analyst Decision
Strong Buy
Buy
Analyst Count
5
9
Target Price
$40.60
$44.11
AVG Volume (30 Days)
337.7K
691.2K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.97
EPS
N/A
1.84
Revenue
$1,448,685,000.00
$868,453,000.00
Revenue This Year
N/A
$19.75
Revenue Next Year
$7.63
$12.88
P/E Ratio
$117.77
$21.67
Revenue Growth
17.93
21.51
52 Week Low
$23.18
$25.52
52 Week High
$47.02
$40.87

Technical Indicators

Market Signals
Indicator
GRDN
HRMY
Relative Strength Index (RSI) 39.73 57.85
Support Level $35.56 $34.87
Resistance Level $38.12 $39.40
Average True Range (ATR) 1.33 1.11
MACD -0.14 -0.02
Stochastic Oscillator 8.21 62.91

Price Performance

Historical Comparison
GRDN
HRMY

About GRDN Guardian Pharmacy Services Inc.

Guardian Pharmacy Services Inc is a pharmacy services company providing technology-enabled services to help residents of long-term health care facilities (LTCFs) adhere to appropriate drug regimens, reducing the cost of care and improving clinical outcomes. The Company provides high-touch clinical, drug dispensing, and administration services tailored to residents in assisted living facilities, behavioral health facilities, and group homes, while also serving residents in all types of LTCFs. It partners with residents, LTCFs, and health plan payors to help reduce errors in drug administration, manage drug regimens, and improve adherence. The Company derives its revenue mainly from the sale of pharmaceutical and medical products.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: